Richmond, VA, March 19, 2015 -- /EPR NETWORK/ -- American International Biotechnology, LLC (AIBioTech), Richmond VA, is proud to announce Dr. Dai (Dave) J. Li as their new Clinical Director. Dr. Li will be conducting clinical trial studies by utilizing the combined approach of diagnostic testing and clinical informatics in the field of precision medicine.
“I am excited about my new roles as the Clinical Director of AIBioTech. AIBioTech is at the forefront of the movement of precision medicine with its state-of-the-art assay portfolios and robust research capabilities especially that are enabled by the powerful Next Generation DNA Sequencing technologies for pharmacogenomics testing and cancer risk assessment. I have no doubt that the integrated approach of the innovative advanced laboratory testing with biomedical informatics as exemplified by the AIBioTech’s business model will provide greater insights of human illnesses propelling the future growth of the corporation and bring substantial value to the future patient care delivery and outcomes”, stated Dr. Li.
Dr. Li obtained his MB/MD at the Sun Yat-Sen University, School of Medicine and Cancer Center in Guangzhou, China, and his MSc/PhD from the University of Texas M.D. Anderson Cancer Center in Houston, Texas. He received additional training in tumor immunology from the Department of Surgery and Organ Transplantation at the University of Texas Health Science Center in Houston, as well as in Clinical Informatics from the Department of Health Informatics at The Johns Hopkins University School of Medicine in Baltimore, Maryland.
He completed a combined residency in medical oncology and laboratory medicine at the Sun Yat-Sen University Cancer Center in Guangzhou, China. Subsequently, he did clinical fellowships in Clinical Pathology at the University of Texas Southwestern Medical Center and Parkland Memorial Hospital in Dallas, Texas, as well as at the Johns Hopkins Hospital in Baltimore, Maryland. Dr. Li’s career spans academic institutions, government and commercial operations including positions at Johns Hopkins Medical Institutions School of Medicine, Wako Chemicals, USA, Inc., the U.S. Food and Drug Administration, Wako Life Sciences and Health Diagnostic Laboratory, Inc.
Dr. Li is a physician certified by the American Medical Association (AMA) and the United States National Board of Medical Examiners holding a permanent ECFMG Certificate. He is also a certified clinical laboratory director by the College of American Pathologists (CAP) and Center for Medicare and Medicaid Services (CMS/CLIA). He is a member of many professional societies including AMA, American Society of Clinical Pathology (ASCP), American Society of Clinical Oncology (ASCO), and American College of Physician Executive (ACPE), American Medical Informatics Association (AMIA), and American Association for the Study of Liver Disease (AASLD), and Endocrine Society. Dr. Li has over twenty publications as an author or co-author in peer-reviewed medical journals, as well as book chapters on oncology drug discovery and development.
Dr. David Bostwick, CEO of AIBioTech, stated that “Dr. Li brings a great breadth of knowledge and experience to AIBioTech. His past work with the FDA, Johns Hopkins and HDL have given him a remarkably complete understanding of clinical needs in the current laboratory environment.”
AIBioTech is a comprehensive contract research organization which provides clinical testing and research and development services to physicians and life science investigators in biotechnology and pharmaceutical companies, academic institutions, and in several different government agencies. It also operates a forensics and paternity testing division under the name Fairfax Identity Laboratories. For more information about its capabilities and services visit the company website at www.aibiotech.com.
Contact-Details: AIBiotech, Kelley W. Randall, 601 Biotech Drive, Richmond VA 23235, 804-915-3837, Krandall@aibiotech.com, www.aibiotech.com